Erectile Dysfunction Due to Arterial Insufficiency Clinical Trial
— IMPASSEOfficial title:
Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study
Verified date | January 2016 |
Source | Medtronic Endovascular |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
The purpose of this study is to determine the proportion of men with known or suspected coronary artery disease (CAD) and/or peripheral arterial disease (PAD) that have angiographic identifiable erectile related artery (ERA) atherosclerotic disease defined as at least one ERA stenosis greater than or equal to 50% (per core lab Quantitative Vascular Analysis - QVA).
Status | Terminated |
Enrollment | 19 |
Est. completion date | March 2012 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 35 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Subject must be undergoing coronary or peripheral angiography for suspected or known coronary or peripheral atherosclerotic disease - Subject must be male = 35 and = 70 years old - Subject must provide written informed consent before any study-related procedures are performed - Subject must agree to comply with study procedures and follow-up for the entire length of the study Exclusion Criteria: - Subject is unable to safely attempt sexual intercourse secondary to severe cardiac disease or other health condition - Subject has a life expectancy of < 12 months - Subject's serum creatinine is > 2.5 mg/dl - Subject has known aorto-iliac occlusive disease, previous AAA endograft procedure or open surgical procedure - Subject has history of prostatic carcinoma requiring surgery (i.e., prostatectomy), pelvic radiation, or hormonal/chemotherapy - Subject has a history of myocardial infarction, stroke, life-threatening arrhythmia, or unstable angina requiring hospitalization within 3 months (90 days) prior to enrollment - Subject has had exposure to PDE5 inhibitor (per subject's concomitant medication list) within the 72 hours prior to the scheduled baseline angiography - Subject has a history of renal transplantation - Subject has a penile implant - Subject has become unstable or has received a maximum radiation dose, increased procedure time, and/or maximum contrast dose (in the Investigator's opinion) from the primary angiographic procedure that would compromise the safety of the subject by proceeding with enrollment into the IMPASSE study |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Prairie Edication and Research Cooperative | Springfield | Illinois |
Lead Sponsor | Collaborator |
---|---|
Medtronic Endovascular | Medtronic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the proportion of men with known or suspected CAD and/or PAD that have angiographic identifiable erectile related artery (ERA) atherosclerotic disease | Identifiable ERA disease is defined as at least one ERA stenosis greater than or equal to 50 percent (per core lab Quantitative Vascular Analysis - QVA) | Baseline through Discharge | No |
Secondary | Procedural Safety | Defined as major adverse event (MAE) rate at 30 days characterized as: 1) Procedure related death (directly related to the ERA DSA portion of the baseline angiography) 2) Occurrence of perineal gangrene or necrosis (penile glans, penile shaft, scrotal or anal) 3) Perineal, penile or anal surgery (including ERA embolization procedures) 4) Renal failure | 30 Days | Yes |
Secondary | To determine the proportion of men with atherosclerotic ERA disease who have erectile dysfunction (ED) through 36 months | ED is defined as a urological assessment survey (UAS) of less than or equal to 21 | 36 months | No |
Secondary | To determine the proportion of men who have atherosclerotic ERA disease and are asymptomatic (i.e., normal erectile function) through 36 months | Normal erectile function is defined as a UAS score greater than 21 | 36 months | No |
Secondary | To determine the proportion of men who have ED without evidence of atherosclerotic ERA disease through 36 months | 36 months | No | |
Secondary | The predictive capacity of ERA atherosclerosis for potential future cardiovascular events* including ED in men with baseline normal erectile function through 36 months | *Cardiovascular events include - CVA, MI, narrowing of a coronary or peripheral artery resulting in revascularization, new onset hypertension, unstable angina and/or cardiovascular death | 36 months | Yes |
Secondary | The predictive capacity of ED for incident cardiovascular events* compared to men without ED found to have healthy pelvic vasculature (< 50% stenosis in erectile relevant arteries) through 36 months | *Cardiovascular events include - CVA, MI, narrowing of a coronary or peripheral artery resulting in revascularization, new onset hypertension, unstable angina and/or cardiovascular death | 36 months | Yes |
Secondary | Evaluation of the Urological Assessment Survey (UAS) from baseline through the 36 month follow-up period | 36 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04050020 -
Platelet-rich Plasma (PRP) Injection for Treatment of Erectile Function
|
Phase 2/Phase 3 | |
Recruiting |
NCT05868668 -
Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain
|
N/A | |
Active, not recruiting |
NCT04434352 -
Low Intensity Shockwave Therapy for Erectile Dysfunction
|
N/A |